Search

Your search keyword '"Novavax Inc. -- Licensing agreements"' showing total 25 results
Start Over Descriptor "Novavax Inc. -- Licensing agreements" Publication Year Range Last 10 years
25 results on '"Novavax Inc. -- Licensing agreements"'

1. Novavax, Sanofi enter licensing agreement to co-commercialize Covid-19 vaccine and develop novel Covid-19-influenza combination vaccines

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has entered into a co-exclusive licensing agreement with Sanofi. The terms of the agreement include: a co-exclusive license [...]

Published
2024

2. Client Novavax, Maker of COVID-19 Vaccine, Signs $1.4 Billion Agreement with Sanofi

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Influenza vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

Massachusetts: Ropes & Gray has issued the following press release: Ropes & Gray represented Novavax Inc., in a co-exclusive licensing agreement with French pharmaceutical company Sanofi to sell Novavax COVID-19 [...]

Published
2024

3. NOVAVAX AND SANOFI ANNOUNCE CO-EXCLUSIVE LICENSING AGREEMENT TO CO-COMMERCIALIZE COVID-19 VACCINE AND DEVELOP NOVEL COVID-19-INFLUENZA COMBINATION VACCINES

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, News, opinion and commentary
Abstract

GAITHERSBURG, Md. -- The following information was released by Novavax, Inc.: Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 [...]

Published
2024

4. Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Provides Novavax with cash and an equity investment totalling approximately [...]

Published
2024

5. Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines - Agreement provides patients with broader access to [...]

Published
2024

6. Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine [...]

Published
2024

7. Sanofi and Novavax sign co-exclusive licensing agreement

Subjects
Novavax Inc. -- Licensing agreements, Euronext Paris S.A. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Health care industry -- Licensing agreements, Securities industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Health care industry, Securities industry, Company licensing agreement, Business
Abstract

M2 EQUITYBITES-May 10, 2024-Sanofi and Novavax sign co-exclusive licensing agreement (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Novavax Inc (Nasdaq:NVAX) announced [...]

Published
2024

8. Sanofi and Novavax sign co-exclusive licensing agreement

Subjects
Novavax Inc. -- Licensing agreements, Euronext Paris S.A. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Health care industry -- Licensing agreements, Securities industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Health care industry, Securities industry, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-May 10, 2024-Sanofi and Novavax sign co-exclusive licensing agreement (C)2024 M2 COMMUNICATIONS French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Novavax Inc (Nasdaq:NVAX) announced on [...]

Published
2024

9. NOVAVAX'S UPDATED COVID-19 VACCINE RECEIVES EMERGENCY USE AUTHORIZATION IN THE REPUBLIC OF KOREA

Subjects
Novavax Inc. -- Licensing agreements, Vaccination, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Company licensing agreement, News, opinion and commentary
Abstract

GAITHERSBURG, Md. -- The following information was released by Novavax, Inc.: Novavaxá'sá partner, áSK bioscience,átoday announced that áNovavax's updated COVID-19 vaccine (NVX-CoV2601) has received Emergency Use Authorization áfromá the Ministry [...]

Published
2023

10. Novavax: Nuvaxovid Approved in South Korea for COVID-19 Active Immunization Booster

Subjects
Novavax Inc. -- Licensing agreements, Immunization, Biotechnology industry -- Licensing agreements, Drug approval, Vaccines -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary, Nuvaxovid (Vaccine) -- Licensing agreements
Abstract

Novavax, Inc. (NVAX) said its partner SK bioscience has received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid for use as a [...]

Published
2023

12. Novavax and SK bioscience Expand Manufacturing Agreement

Subjects
Novavax Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Company licensing agreement, Business, international
Abstract

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK [...]

Published
2021

13. Novavax and SK bioscience Expand Manufacturing Agreement

Subjects
Novavax Inc. -- Licensing agreements, Vaccines -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

GAITHERSBURG: Novavax, Inc has issued the following news release: Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, [...]

Published
2021

14. NOVAVAX AND SK BIOSCIENCE EXPAND MANUFACTURING AGREEMENT

Subjects
Novavax Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Antigens, Vaccines -- Licensing agreements, Company licensing agreement, News, opinion and commentary
Abstract

GAITHERSBURG, Md. -- The following information was released by Novavax, Inc.: - Novavax secures additional manufacturing capacity through 2022 - SK bioscience secures long-term license to supply NVX-CoV2373 for the [...]

Published
2021

15. Serum Institute's Covovax Anticipated Launch By September, Says CEO Adar Poonawalla

Subjects
Novavax Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international, Law
Abstract

Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of Covid-19 vaccine Covovax have begun in India and the company hopes to launch it by September [...]

Published
2021

16. Covovax trials begin in India, hope to launch it by Sept 2021: Adar Poonawalla

Subjects
Novavax Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international, Law
Abstract

Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of Covid-19 vaccine Covovax have begun in India and the company hopes to launch it by September [...]

Published
2021

17. Novavax expands collaboration and license agreement with SK bioscience, Co. Limited for NVX-CoV2373

Subjects
Novavax Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-December 24, 2021-Novavax expands collaboration and license agreement with SK bioscience, Co. Limited for NVX-CoV2373 (C)2021 M2 COMMUNICATIONS Novavax, Inc. (Nasdaq: NVAX), a biotechnology company, announced on Thursday that [...]

Published
2021

18. Novavax expands collaboration and license agreement with SK bioscience, Co. Limited for NVX-CoV2373

Subjects
Novavax Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Company licensing agreement, Business
Abstract

M2 EQUITYBITES-December 24, 2021-Novavax expands collaboration and license agreement with SK bioscience, Co. Limited for NVX-CoV2373 (C)2021 M2 COMMUNICATIONS http://www.m2.com Novavax, Inc. (Nasdaq: NVAX), a biotechnology company, announced on Thursday [...]

Published
2021

19. Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea

Subjects
Novavax Inc. -- Licensing agreements, BioScience Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Existing partnership for manufacture of NVX-CoV2373 expanded to increase production capacity and supply vaccine to the Korean Government GAITHERSBURG, Md., Feb. 15, 2021 (GLOBE NEWSWIRE) [...]

Published
2021

20. NOVAVAX ANNOUNCES EXPANDED COLLABORATION AND LICENSE AGREEMENT WITH SK BIOSCIENCE FOR 40 MILLION DOSES OF COVID-19 VACCINE FOR SOUTH KOREA

Subjects
Novavax Inc. -- Licensing agreements, BioScience Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, News, opinion and commentary
Abstract

GAITHERSBURG, Md. -- The following information was released by Novavax, Inc.: Existing partnership for manufacture of NVX-CoV2373 expanded to increase production capacity and supply vaccine to the Korean Government GAITHERSBURG, [...]

Published
2021

21. Novavax and Serum Institute of India Announce Development and Commercial Collaboration

Subjects
Novavax Inc. -- Licensing agreements, Vaccines -- Licensing agreements, Recombinant proteins, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international, Coalition for Epidemic Preparedness Innovations
Abstract

(GlobeNewswire) - Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a license agreement with Serum Institute of India Private Limited (SIIPL) [...]

Published
2020

22. Novavax and Serum Institute of India Announce Development and Commercial Collaboration

Subjects
Novavax Inc. -- Licensing agreements, Vaccines -- Licensing agreements, Recombinant proteins, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international, Law, Coalition for Epidemic Preparedness Innovations
Abstract

(GlobeNewswire) - Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a license agreement with Serum Institute of India Private Limited (SIIPL) [...]

Published
2020

23. Serum Institute collaborates with Novavax for malaria vaccine

Subjects
Novavax Inc. -- Licensing agreements, Antigens, Vaccines -- Licensing agreements, Malaria vaccines -- Licensing agreements, Malaria, Pharmaceutical industry -- Licensing agreements, Immune response, Plasmodium falciparum, Clinical trials, Communicable diseases, Biotechnology industries, Diseases, Company licensing agreement, Biotechnology industry, University of Oxford
Abstract

NovavaxÇÖ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University US based Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for [...]

Published
2020

24. Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Subjects
Novavax Inc. -- Licensing agreements, Antigens, Vaccines -- Licensing agreements, Malaria vaccines -- Licensing agreements, Medical research, Malaria, Pharmaceutical industry -- Licensing agreements, Immune response, Plasmodium falciparum, Communicable diseases, Biotechnology industries, Diseases, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

GAITHERSBURG, Mar 11, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Novavax' proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University -- Phase [...]

Published
2020

25. Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Subjects
Novavax Inc. -- Licensing agreements, Antigens, Vaccines -- Licensing agreements, Malaria vaccines -- Licensing agreements, Medical research, Malaria, Pharmaceutical industry -- Licensing agreements, Immune response, Communicable diseases, Biotechnology industries, Diseases, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - Novavax' proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University - Phase 2b clinical efficacy study [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results